Search

everythinglearnresearchcommunity

for

Search:↓

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

DM and AA may share a common cause.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

A woman with lupus developed rare skin growths that went away on their own.

Methotrexate is not proven to maintain remission in ulcerative colitis.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

Severe digestive issues in DRESS need early endoscopy for better treatment.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

MR antagonists may improve skin health and wound healing, especially in aging.

A multi-drug treatment can effectively clear extensive calcinosis in juvenile dermatomyositis.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Mycophenolate mofetil is effective for treating severe lupus nephritis in children.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

High-dose corticosteroid treatment helped improve symptoms in a patient with Adult Onset Still Disease.

Individualized treatments may help manage Dercum's disease symptoms.

NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.

Inflammation in rheumatoid arthritis increases steroid activation in cells, reducing inflammation.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.

Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Blocking the mineralocorticoid receptor improves wound healing by reducing inflammation and promoting blood vessel growth.

Many patients with Giant Cell Arteritis did not follow their steroid treatment plans properly.

Co-trimoxazole may help treat autoimmune diseases.

A patient's grey hair regained color during treatment with adalimumab.

Most patients with cutaneous dermatomyositis either improved or remained stable over 3.5 years.